Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of mRNA-1045 and mRNA-1230 in Healthy Older Adults
NCT05585632Phase 1Completed
- Sponsor
- Moderna Inc
- Start
- Oct 2022
- Primary completion
- Feb 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 3
01
Overview
Phase 1, randomised, triple-blind trial of mRNA-1045 and mRNA-1230 in influenza, respiratory syncytial virus infection (RSV) and coronavirus disease 2019 (COVID-19) (9 arms), sponsored by Moderna Inc. Primary endpoints: Solicited Local and Systemic Adverse Reactions at Day 8, Unsolicited Adverse Events at Day 29 and 2 more. Started Oct 2022; status: completed.
02
Drugs
mRNA-1045mRNA-1230
03
Conditions
influenzarespiratory syncytial virus infection (RSV)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05585632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05585632.